BioHarvest Sciences (BHST) Investor presentation summary
Event summary combining transcript, slides, and related documents.
Investor presentation summary
22 Oct, 2026Business model and guidance
2026 revenue guidance: $37–40M total, including $33–35M D2C and $4–5M CDMO, excluding internal VINIA transfers.
D2C is led by VINIA, with subscription sales and planned expansion into hydration, chews and hot beverages; the strategy is to move the business toward profitability and disciplined cash generation.
The platform combines D2C products with CDMO development, manufacturing and potential royalty economics across four industries.
2025 revenue was reported at $35M, with $100M in cumulative sales; the presentation also cites 15 patents.
Plant cell platform and infrastructure
Proprietary plant-cell culture uses a cell line derived from one plant, then propagates it in industrial bioreactors to produce plant-derived molecules at scale.
Claimed platform benefits include controlled consistency and purity, non-GMO production, lower COGS versus extraction, and enhanced potency through elicitation methods.
Current annual production capacity is 20–25 tons, with a stated expansion path to 75+ tons; historical facility capex was $5M.
AI-supported computer vision, sensor data fusion and predictive models are intended to improve yield, consistency, discovery and scale-up throughput.
Commercial and development pipeline
Four third-party programs are advancing across cosmetics and fragrances, nutraceuticals, pharma and biotech, and nutrition and sweeteners.
A 20-ton manufacturing and supply agreement for a rare botanical luxury fragrance is expected to generate $20–30M revenue in 2027–2028.
The fragrance program completed Stage 1 and entered Stage 2; a manufacturing and supply agreement was signed in Q3 2026.
The Saffron Tech program completed Stage 1 in Q2 2026; the Tate & Lyle program added a second sweetener molecule after the platform demonstrated production capability for the targeted molecule in Q4 2026.
CDMO economics progress from paid development stages to commercial manufacturing revenue and potential royalties or ownership participation.
Latest events from BioHarvest Sciences
- Proprietary plant cell culture drives revenue growth and expansion, with $37–$40M projected this year.BHST
H.C. Wainwright 28th Annual Global Investment Conference - Patented plant cell culture platform drives scalable growth and strong revenue outlook.BHST
Q3 Investor Summit Group Virtual Conference 2026 - Patented cell culture platform secures $20–30M fragrance deal, targets $40M revenue and profitability.BHST
Canaccord Genuity's 46th Annual Growth Conference - Proprietary plant cell platform and D2C/CDMO engines drive projected $37–40M 2026 revenue.BHST
Corporate presentation - Secured first CDMO fragrance contract, driving revenue growth and revised guidance for 2026.BHST
Q2 2026 - Q1 revenue up 8% to $8.5M, CDMO revenue up 135%, net loss $2.6M, gross margin 59%.BHST
Q1 2026 - Plant-based exosome breakthrough enables new high-margin markets and a novel skincare launch.BHST
Status Update - Q1 revenue up 47% to $7.9M, gross margin 58.5%, and major CDMO contract advanced.BHST
Q1 2025 - Q4 revenue up 62%, gross margin at 57%, and major CDMO deal drive strong 2025 outlook.BHST
Q4 2024